GSK’s China Ex-head Returns To China For Anti-Bribery Probe
This article was originally published in PharmAsia News
Mark Reilly, former head of GlaxoSmithKline Plc.’s China operations, returned to China’s Changsha city a few weeks ago to assist and provide relevant information for a police investigation, during which he is banned from leaving the country.
You may also be interested in...
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.
Due to strained resources and the slew of emergency use authorizations being requested by sponsors because of the COVID-19 crisis, the agency will now periodically publish Notices of Availabilities in the Federal Register instead of publishing immediately as the EUAs are handed out. However, companies will still get their NOA letters and can start marketing their products, and the agency will post the announcements sooner on its website.